Market Newsdesk

CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share.

The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million. Under the program, Cosmos Health may repurchase shares from time to time in the open market, through privately negotiated transactions, or through other permitted means, in accordance with SEC Rules 10b5-1 and 10b-18 and other applicable rules and regulations.

The Company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the Company’s sole discretion.

Greg Siokas, CEO of Cosmos Health, stated: “Reaching over five million shares repurchased underscores our continued commitment to the program and our belief that the Company’s shares remain undervalued relative to the strength and potential of our business.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications
[email protected]

• ASNR considers as satisfactory the safety program proposed by newcleo for its planned MOX fuel facility.
  The Company will incorporate the insights gained through the ASNR opinion in the ongoing development and planning of its project.

• SGPI informs the Company that the amount of money raised by newcleo along with its level of development has surpassed the scope of the France 2030 program, leading to different forms of collaboration with French institutions.

PARIS, July 17, 2026 (GLOBE NEWSWIRE) — newcleo (or the “Company”), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, today announced a significant regulatory milestone for its planned mixed-oxide (“MOX”) fuel facility in France. The company is also entering a new phase of collaboration with French authorities following the evaluation of newcleo’s application for Phase 2 of the France 2030 innovative nuclear reactor program.

French safety approach considered satisfactory by the ASNR

The French Nuclear Safety and Radiation Protection Authority (Autorité de sûreté nucléaire et de radioprotection) (“ASNR”) has published on 13 July 2026 its opinion on all the safety features proposed by newcleo for its planned French MOX fuel facility, concluding that the provisions adopted by the Company for its safety approach are satisfactory at this stage.

In December 2024, newcleo submitted a safety approach dossier to the French nuclear safety authority for its planned MOX fuel fabrication facility in France.

Following its review, the ASNR has concluded that the provisions proposed by newcleo for the facility’s safety demonstrations which are envisioned are satisfactory and, overall, are capable of meeting the objectives established under the applicable French nuclear safety framework.

The ASNR’s opinion also identifies areas to be developed further as the project advances. newcleo intends to incorporate the ASNR’s recommendations into the facility design in support of a future construction license application.

The French review gives newcleo practical experience in developing the safety case for a first-of-a-kind MOX fuel manufacturing facility.

The Company is also progressing through a similar regulatory process for its Lead-Cooled Fast Reactor (LFR) design and is currently awaiting the opinion of the ASNR on its proposed safety features.

In parallel, newcleo is carrying out a three-month public debate on its proposed French LFR and MOX fuel facility projects, becoming the first private developer of an innovative reactor technology to complete this key stage of stakeholder engagement in France.

The Company will carefully assess the conclusions of the National Commission for the Public Debate (Comission Nationale du Dèbat Public), incorporating the insights gained into the ongoing development and planning of its projects.

France 2030 innovative reactor program

Following the detailed evaluation of newcleo’s application for Phase 2 of the France 2030, the General Secretariat for Investments (Secrétariat general pour l’investissement) (“SGPI”) concluded that newcleo has reached a stage of development that exceeds the scope of the program. Since participating in the program, the Company has raised a significant amount of capital, which highlights the program’s catalytic effect.

newcleo has also achieved a significant international presence, and, on May 27, 2026, announced that it had entered into a definitive agreement for a business combination with NewHold Investment Corp. III (NASDAQ: NHIC) in a transaction that, upon closing, would result in newcleo becoming a U.S.-listed public company. The transaction values newcleo at a pre-money equity value of approximately $2.4 billion and is expected to provide up to $429 million in gross proceeds, assuming no redemptions by SPAC shareholders.

As a result, considering these developments, which were obtained thanks also to the France 2030’s initial support to the Company in 2023, a limited additional contribution of public funding to the project would be marginal and ineffective.

In this context, the French State will continue working with newcleo to identify other forms of cooperation in the next stage of the Company’s development, including through licensing support with the ASNR, state services in connection with the Company’s proposed projects in the French territory and through export-facing initiatives.

Stefano Buono, CEO and Founder of

new

cleo said: “We welcome the ASNR’s positive opinion, which reflects years of work by the teams developing our MOX fuel facilities. We are proud to contribute to France’s nuclear industry, and we thank France 2030 for its support, which has accelerated our technology development, strengthened our presence in France, fostered strategic partnerships, and attracted private investment.”

About

new

cleo

newcleo is an innovative nuclear energy company developing AMRs cooled by liquid lead, and facilities to produce nuclear fuel from recycled nuclear waste, with the goal of delivering abundant, competitive, low-carbon energy. The company was founded by physicist-entrepreneur Stefano Buono following the USD $3.9 billion sale of his previous venture – Nasdaq-listed nuclear medicine company Advanced Accelerator Applications – to Novartis. With over USD $80 million in revenue, other income, and financial income in 2024 including from its operating companies, approximately USD $780 million in private funding, and more than 900 highly skilled employees across Europe and the United States, the company has built a network of over 100 industry partnerships and supports its growth through the targeted acquisition and vertical integration of key companies in the nuclear supply chain.

For more information visit www.newcleo.com/investors/

Important Information for Investors and Shareholders

NewHold and newcleo have filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form F-4 (as may be amended, the “Registration Statement”), which includes a preliminary proxy statement of NewHold and a prospectus of newcleo (the “Proxy Statement/Prospectus”) in connection with the proposed business combination between NewHold and newcleo (the “Business Combination”), the private placements of securities in connection with the Business Combination, if any (the “Private Placement Transactions”), and the other transactions contemplated by the Business Combination Agreement and/or as described in this communication (together with the Business Combination and the Private Placement Transactions, the “Proposed Transactions”). The definitive proxy statement and other relevant documents will be mailed to shareholders of NewHold as of the record date to be established for voting on the Business Combination and other matters as described in the Proxy Statement/Prospectus. NewHold and/or newcleo will also file other documents regarding the Proposed Transactions with the SEC. This communication does not contain all of the information that should be considered concerning the Proposed Transactions and is not intended to form the basis of any investment decision or any other decision in respect of the Proposed Transactions. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, SHAREHOLDERS OF NEWHOLD AND OTHER INTERESTED PARTIES ARE URGED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT/PROSPECTUS, AND AMENDMENTS THERETO, AND THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH NEWHOLD’S SOLICITATION OF PROXIES FOR THE EXTRAORDINARY GENERAL MEETING OF ITS SHAREHOLDERS TO BE HELD TO APPROVE THE PROPOSED TRANSACTIONS AND OTHER MATTERS AS DESCRIBED IN THE PROXY STATEMENT/PROSPECTUS BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT NEWHOLD, NEWCLEO AND THE PROPOSED TRANSACTIONS. Investors and security holders will also be able to obtain copies of the Registration Statement and the Proxy Statement/Prospectus and all other documents filed or to be filed with the SEC by NewHold and newcleo, without charge, once available, on the SEC’s website at www.sec.gov, or by directing a request to: NewHold Investment Corp. III, 52 Vanderbilt Avenue, Suite 2005, New York, New York 10017, or to: newcleo Ltd., 55 South Audley Street, London, W1K 2QH, United Kingdom.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE PROPOSED TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION, OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

The securities to be issued by newcleo in connection with the Proposed Transactions have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), except pursuant to the Registration Statement once declared effective by the SEC, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

Participants in the Solicitation

NewHold, newcleo and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies from NewHold shareholders in connection with the Business Combination. A list of the names of NewHold’s directors and executive officers and information regarding their interests in the Business Combination and their ownership of NewHold’s securities is, or will be, contained in NewHold’s filings with the SEC. Additional information regarding the interests of the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from NewHold shareholders in connection with the Business Combination, including the names and interests of newcleo’s directors and executive officers, will be set forth in the Proxy Statement/Prospectus, which is expected to be filed by NewHold and newcleo with the SEC. Investors and security holders may obtain free copies of these documents as described above.

No Offer or Solicitation

This communication is for informational purposes only and is not a proxy statement or solicitation of a proxy, consent or authorization, with respect to any securities or in respect of the Proposed Transactions and shall not constitute an offer to sell or exchange, or a solicitation of an offer to buy or exchange the securities of NewHold or newcleo, or any commodity or instrument or related derivative, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the Securities Act.

Forward-Looking Statements

This press release contains certain forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections, as well as beliefs and assumptions made by management, and include statements that are not historical facts. Forward-looking statements generally may be identified by the use of words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “may,” “should,” “will,” “would,” “could,” “potential,” “future,” “continue,” “strategy,” “opportunity” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding newcleo’s business strategy, plans, objectives, market opportunities, growth prospects, development and commercialization of technologies, partnerships, regulatory matters, operational performance, financial outlook and other future events or developments. Forward-looking statements are subject to risks, uncertainties and assumptions, many of which are beyond newcleo’s control, that could cause actual results to differ materially from those expressed in or implied by such statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and newcleo undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. No assurance can be given that any future results, events or circumstances reflected in the forward-looking statements will be achieved or occur.

For media and investor enquiries

Investor contact

[email protected]

Newcleo press office

[email protected]

US media enquiries

[email protected]

European media enquiries

[email protected]

LONDON, July 17, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE: NVT) (“nVent”), a global leader in electrical connection and protection solutions, will report second quarter 2026 financial results on Friday, July 31, 2026.

The financial results will be posted on the company’s website at http://investors.nvent.com. The company will issue a news release when the earnings materials are publicly available, including a link to those documents.

The company will also hold a conference call with analysts and investors at 9:00 a.m. ET. Related presentation materials will be posted to http://investors.nvent.com prior to the conference call.

Conference Call and Webcast Details

The call can be accessed via webcast at http://investors.nvent.com or by dialing 1-833-630-1071 or 1-412-317-1832. Once available, a replay of the conference call will be accessible through August 14, 2026, by dialing 1-855-669-9658 or 1-412-317-0088, along with the access code 3803194.

About nVent

nVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high performance products and solutions that connect and protect some of the world’s most sensitive equipment, buildings and critical processes. We offer a comprehensive range of systems protection and electrical connections solutions across industry-leading brands that are recognized globally for quality, reliability and innovation. Our principal office is in London and our management office in the United States is in Minneapolis. Our robust portfolio of leading electrical product brands dates back more than 100 years and includes nVent CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE. Learn more at www.nvent.com.

nVent, CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE are trademarks owned or licensed by nVent Services GmbH or its affiliates.

Investor Contact

Tony Riter
Vice President, Investor Relations
nVent
763.204.7750
[email protected]

Media Contact

Kevin H. King
Vice President, Global Communications
nVent
763.291.0526
[email protected]

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) — E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor in the strategic business combination between Glucotrack, Inc. (Nasdaq: GCTK) and Lōkahi Therapeutics, and as exclusive placement agent for a concurrent convertible note financing of approximately $5.7 million to support the combined company’s post-closing growth.

The transaction establishes a publicly traded, capital-efficient healthcare platform, pairing Lōkahi Therapeutics’ AI-driven asset sourcing and development capabilities with Glucotrack’s Nasdaq listing to create a scalable framework for identifying, acquiring, and advancing differentiated healthcare assets. Lōkahi Therapeutics becomes the operating and controlling business of the combined company, while Glucotrack’s continuous blood glucose monitoring (CBGM) business will continue to operate as a wholly owned subsidiary.

The convertible note financing was placed with institutional investors, with net proceeds expected to fund Lōkahi Therapeutics’ post-closing operations and strategic initiatives as the combined company executes its growth strategy.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, commented: “We are proud to have supported both the business combination and the accompanying financing, delivering a comprehensive capital markets solution that positions the combined company for its next phase of growth. This transaction reflects E.F. Hutton’s continued commitment to guiding clients through strategic transactions and capital formation. We appreciate the opportunity to have worked alongside Glucotrack and Lōkahi Therapeutics and look forward to following the combined company’s progress.”

About E.F. Hutton & Co.

E.F. Hutton & Co. is a full-service investment bank and broker-dealer headquartered in New York City, serving corporations, financial sponsors, and institutional investors across the U.S., Asia, Europe, the UAE, and Latin America. We provide a comprehensive range of investment banking and capital markets services across our specialized divisions, delivering integrated solutions at every stage of the capital lifecycle. For more information, please visit www.efhutton.com.

Contact Information

E.F. Hutton & Co.
[email protected]
www.efhutton.com   
(212) 970-3700

CEDAR RAPIDS, Iowa, July 17, 2026 (GLOBE NEWSWIRE) — United Fire Group, Inc. (Nasdaq: UFCS) (UFG) announced today that its second quarter 2026 earnings results will be released after the market closes on Monday, August 3, 2026. An earnings call will be held on Tuesday, August 4, 2026 at 9 a.m. CT to allow securities analysts, shareholders and other interested parties the opportunity to hear management discuss the company’s second quarter 2026 results.

Teleconference: Dial-in information for the call is toll-free 1-844-492-3723 (international 1-412-542-4184). Participants should request to join the United Fire Group call. The event will be archived and available for digital replay through August 11, 2026. The replay access information is toll-free 1-855-669-9658 (international 1-412-317-0088); access code no. 2119197.

Webcast: A webcast of the teleconference can be accessed at https://ir.ufginsurance.com/events-and-presentations/ or https://event.choruscall.com/mediaframe/webcast.html?webcastid=sEg6VEdp. The archived audio webcast will be available for one year.

Transcript: A transcript of the teleconference will be available on the company’s website soon after the completion of the teleconference.

About UFG:

Founded in 1946 as United Fire & Casualty Company, UFG, through its insurance company subsidiaries, is engaged in the business of writing property and casualty insurance. The company is licensed as a property and casualty insurer in 50 states and the District of Columbia, and is represented by approximately 850 independent agencies. A.M. Best Company assigns a rating of “A-” (Excellent) for members of the United Fire & Casualty Group. For more information about UFG, visit www.ufginsurance.com.

Contact:

Investor relations

Email: [email protected]

Media inquiries

Email: [email protected]

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) — Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”).

The Complaint alleges that Defendants made materially false and misleading statements regarding the true state of Regeneron’s Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Regeneron’s securities at artificially inflated prices.

The Complaint alleges that the full truth finally emerged after-market on May 15, 2026, when Regeneron issued a press release announcing that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).”

The Complaint also alleges that the investors and analysts again reacted promptly to Regeneron’s revelation. The Complaint continues to allege that the price of Regeneron’s common stock declined even further from a closing market price of $698.25 per share on May 15, 2026, Regeneron’s stock price fell to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.

Investors who purchased or otherwise acquired shares of Regeneron should contact the Firm prior to the September 14, 2026 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].

Please visit our website at http://www.gme-law.com for more information about the firm.

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [²¹²Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.

About [²¹²Pb]VMT-α-NET

Perspective designed [²¹²Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:

Annie J. Cheng, CFA
[email protected]

ENTENTE Network of Companies

Katie Morris, PhD
[email protected]

LONDON, July 17, 2026 (GLOBE NEWSWIRE) — Roundtable (Nasdaq: RTB), the only AI-powered, DeFi-enabled enterprise media platform, today announced a comprehensive technology partnership with Mario Nawfal, whose content generates more than 1 billion monthly video views. Under the partnership, Roundtable will power Nawfal’s non-social digital platform, marionawfal.com, including publishing, monetization, syndication and business operations through its fully integrated technology stack.

Nawfal’s legendary portfolio of exclusive, long-form interviews with global business, technology and political leaders will be distributed through his own domain on Roundtable’s Web3 platform. His social media presence on X, including 24/7 global news coverage, will remain unchanged. MarioNawfal.com will serve as his owned-and-operated destination and secure IP vault.

“Roundtable’s platform is undoubtedly transformative for the professional media industry,” said Nawfal, who has emerged as a major force in global news. “Their technology provides advantages only DeFi, AI and on-chain publishing can offer. I believe this platform can help restore independence and influence to high-integrity journalism.”

“The world’s most innovative, passionate, modern journalist is the perfect partner to unveil the features of the world’s most powerful digital media platform, said Roundtable CEO, James Heckman. “In a crowded marketplace, Mario has risen to the top, maintaining his civility and objectivity – and so we’re thrilled to include him with our premium media partners.

“The confidence Roundtable’s team brings, with three decades of major media technology leadership experience, made the decision to platform MarioNawfal.com on Roundtable simple,” said Nawfal’s CEO, Wahid Chammis. “Frankly, no other platform provides the full technology stack, and Roundtable was the only company to invest early enough to fully leverage AI, DeFi and blockchain. As a result, the industry’s most sophisticated media operating system is positioned to help professional media finally control its own assets and destiny.”

About Roundtable (RTB Digital, Inc.)

Roundtable (NASDAQ: RTB) is the world’s only AI/DeFi-powered Enterprise Media Platform, integrating distribution, publishing, monetization, community, syndication and DeFi payment operations. The Web3 platform was developed over years by CTO Eyal Hertzog, inventor of DeFi technology, and co-founder James Heckman, creator of the first social network, blogging platform, premium ad marketplace (PMP), social-targeted ad platform, and led digital strategy for News Corp and Yahoo. For more information, visit rtb.io.

About Mario Nawfal and Citizen Journalism Network (CJN)

Founded by Mario Nawfal, CJN is a leading digital media network and corporate accelerator, which operates a dual-model ecosystem structured around high-impact media and a proprietary venture incubation. CJN is one of the largest decentralized digital broadcasting networks globally, specializing real-time, interactive breaking news, financial markets, and technology. The network generates significant global visibility, facilitating large-scale public engagement and audience capture.

Cautionary Note Regarding Forward-Looking Statements

This press release includes information that constitutes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such forward-looking statements include statements that are characterized by future or conditional words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate,” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such forward-looking statements include statements regarding the timing and effects of the merger transaction and the integration of the business of RTB into the combined post-merger company and the effects of the overall merger transaction and future operations of the post-merger company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results to differ materially from those expressed in or contemplated by the forward-looking statements, such as the post-merger company being able to maintain its listing on Nasdaq for the common stock, having sufficient capital for its operations and planned business expansion, and developing its business and capturing users for its services. Other risk factors affecting the Company are discussed in detail in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

Public Relations Contact:

Mehab Qureshi, RTB Digital, Inc.
+91 90289 77198, [email protected]